LQDA has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Liquidia Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, May 8th. Wedbush reissued a “buy” rating and set a $50.00 price objective on shares of Liquidia Technologies in a research report on Friday, June 28th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $31.80.
Shares of LQDA stock traded down $0.45 during trading hours on Thursday, hitting $6.35. 27,073 shares of the company’s stock traded hands, compared to its average volume of 38,519. The stock has a fifty day moving average price of $7.99. Liquidia Technologies has a 12-month low of $6.27 and a 12-month high of $38.46. The firm has a market cap of $136.28 million and a PE ratio of -0.85. The company has a debt-to-equity ratio of 0.46, a quick ratio of 5.57 and a current ratio of 5.57.
Hedge funds have recently modified their holdings of the company. New York State Common Retirement Fund bought a new stake in Liquidia Technologies in the 4th quarter valued at about $96,000. BlackRock Inc. lifted its stake in shares of Liquidia Technologies by 7.1% in the fourth quarter. BlackRock Inc. now owns 231,400 shares of the company’s stock worth $5,011,000 after buying an additional 15,415 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Liquidia Technologies in the fourth quarter worth about $403,000. Northern Trust Corp lifted its stake in shares of Liquidia Technologies by 9.5% in the fourth quarter. Northern Trust Corp now owns 56,333 shares of the company’s stock worth $1,221,000 after buying an additional 4,864 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Liquidia Technologies by 50.1% in the fourth quarter. Geode Capital Management LLC now owns 49,319 shares of the company’s stock worth $1,068,000 after buying an additional 16,453 shares in the last quarter. 56.37% of the stock is owned by hedge funds and other institutional investors.
About Liquidia Technologies
Liquidia Technologies, Inc, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension.
Featured Story: Total Return
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.